Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 11
Submit an article Journal homepage
302
Views
29
CrossRef citations to date
0
Altmetric
Original Article

Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment

Julia Carolin Stingl (formerly Kirchheiner) Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, University Ulm, Germany
,
Sumit Parmar Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, University Ulm, Germany
,
Ariana Huber-Wechselberger Institute of Medical and Laboratory Diagnostics, Elisabethinen Hospital Linz, Austria
,
Alexander Kainz Department of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria
,
Wilfried Renner Clinical Institute of Medical and Laboratory Diagnostics, Medical University Graz, Austria
,
Angela Seeringer Institute of Pharmacology of Natural Compounds and Clinical Pharmacology, University Ulm, Germany
,
Jürgen Brockmöller Department of Clinical Pharmacology, University Medical Center, University Göttingen, Germany
,
Uwe Langsenlehner Internal Outpatient Department, Graz, Austria
,
Peter Krippl Department of Internal Medicine, General Hospital Fürstenfeld, Austria
&
Elisabeth Haschke-Becher Institute of Medical and Laboratory Diagnostics, Elisabethinen Hospital Linz, AustriaCorrespondence[email protected]
 show all
Pages 2535-2542 | Accepted 23 Aug 2010, Published online: 17 Sep 2010

References

  • Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-18
  • Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74
  • Lash TL, Lien EA, Sorensen HT, et al. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009;10:825-33
  • Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009;9:576-86
  • Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-36
  • Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-93
  • Bijl MJ, van Schaik RH, Lammers LA, et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009;118:125-30
  • Ramon YCT, Altes A, Pare L, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010;119:33-8
  • Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008;99:995-9
  • Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21
  • Newman WG, Hadfield KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008;14:5913-18
  • Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-58
  • Okishiro M, Taguchi T, Jin Kim S, et al. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009;115:952-61
  • Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9:R7
  • Wegman P, Vainikka L, Stal O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005;7:R284-90
  • Goetz M, Berry D, Klein T, Consortium atITP. Cancer Res 2009;69(Suppl.) Abstract 33
  • Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9
  • Lim YC, Li L, Desta Z, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2006;318:503-12
  • Higgins MJ, Rae JM, Flockhart DA, et al. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Canc Netw 2009;7:203-13
  • Langsenlehner U, Wolf G, Langsenlehner T, et al. Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian ‘tumor of breast tissue: incidence, genetics, and environmental risk factors’ study. Breast Cancer Res Treat 2008;109:297-304
  • Krippl P, Langsenlehner U, Samonigg H, et al. Vascular endothelial growth factor in predicting outcome in breast cancer. Clin Cancer Res 2004;10:8752-3
  • Brauch H, Murdter TE, Eichelbaum M, et al. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009;55:1770-82
  • Xu Y, Sun Y, Yao L, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008;19:1423-9
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.